[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:stag2-gene":3},{"name":4,"total":5,"recruiting":5,"trials":6},"STAG2 Gene",4,[7,15,21,27],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06313437","Revumenib in Combination With 7+3 + Midostaurin in AML",[11],"Phase 1","RECRUITING","2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.835411Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT04659616","Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia",[11],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:28.717298Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT06152809","CIML NK Cells With Venetoclax for AML",[11],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.162326Z",{"nct_id":28,"title":29,"phases":30,"status":12,"updated_at":32,"content_modified":33},"NCT04588922","Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML",[31],"Phase 1\u002FPhase 2","2026-08-26T02:17:16.980188Z","2026-05-05T02:43:28.806272Z"]